ArticleJournal of cancer research and clinical oncology2015
Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients.
Article in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Prognostic Significance of SOCS3 in Patients With Solid Tumors: A Meta-Analysis.Frontiers in surgery · 2021Pooled it
- Interplay between pathogen-mediated immune evasion and innate immune negative regulation in gastrointestinal tumors.Frontiers in immunology · 2026Review
- SOCS3: An Immunological Biomarker Offering Potential Therapeutic Targets for Malignant Tumors.Biological procedures online · 2025Review
- Long non-coding RNA-MIR181A1HG acts as an oncogene and contributes to invasion and metastasis in gastric cancer.Oncogene · 2025Article
- The SOCS-1 -1478CA/del functional polymorphism (rs33989964) is associated with gastric cancer but is unrelated to overall survival.Molecular biology reports · 2023Article
- SOCS3 gene silencing does not occur through methylation and mutations in gastric cancer.Human cell · 2022Article
- Comprehensive analysis of suppressor of cytokine signaling proteins in human breast Cancer.BMC cancer · 2021Article
- Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Knockdown of m6A methyltransferase METTL3 in gastric cancer cells results in suppression of cell proliferation.Oncology letters · 2020Article
- Article
- The Expression of SOCS and NF-ϰB p65 in Hypopharyngeal Carcinoma.Iranian journal of public health · 2018Article
- Article
- Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p.Molecular cancer · 2017Article
- Genetic Alterations in Gastric Cancer Associated withFrontiers in medicine · 2017Review
- Low expression of MAP1LC3B, associated with low Beclin-1, predicts lymph node metastasis and poor prognosis of gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML.Journal of hematology & oncology · 2016Article
- Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- 15-Deoxy-Δ(12,14)-prostaglandin J2 Induces Apoptosis and Upregulates SOCS3 in Human Thyroid Cancer Cells.PPAR research · 2016Article
- The role of cullin proteins in gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- miRNA-101 inhibits ovarian cancer cells proliferation and invasion by down-regulating expression of SOCS-2.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesInflammation plays an important role in gastric cancer (GC) development and progression. Suppressor of cytokine signaling (SOCS)-1 and SOCS-3 negatively regulate proinflammatory cytokine signaling; however, their prognostic significance in GC remains unknown. We evaluated the clinicopathological correlation and prognostic significance of SOCS-1 and SOCS-3 in GC.
methodsSOCS-1 and SOCS-3 mRNA levels were analyzed in 80 paired gastric tumor and adjacent normal mucosal tissues using a microarray dataset from the Gene Expression Omnibus. Univariate and multivariate analyses were performed to investigate the prognostic impact of SOCS-1 and SOCS-3 immunohistochemical expression on overall survival (OS) and relapse-free survival (RFS) in 186 consecutive GC patients who underwent curative surgery.
resultsSOCS-1 and SOCS-3 mRNA expression levels were lower in gastric tumor tissues than in matched normal mucosa. OS and RFS were significantly longer in the high SOCS-1 and SOCS-3 expression groups than in their corresponding low expression groups (p < 0.05). High simultaneous SOCS-1 and SOCS-3 expression were associated with longer OS compared with low simultaneous SOCS-1 and SOCS-3 expression (68.8 vs. 22.2 months; p < 0.001). SOCS-1 [hazards ratio (HR) 0.54, 95 % confidence interval (CI) 0.33-0.87, p = 0.011] and SOCS-3 (HR 0.46, 95 % CI 0.26-0.80, p = 0.006) were independent prognostic factors for OS. Only SOCS-1 (HR 0.20, 95 % CI 0.11-0.38, p = 0.006) was an independent prognostic factor for RFS.
conclusionLow SOCS-1 and SOCS-3 expression are poor prognostic indicators in GC. GC patients with low SOCS-1 and SOCS-3 expression need close follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.